Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now early-phase tilt small index

Tauopathies: early-phase trial registry

4 of 6 indexed Tauopathies trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,866 of 28,707 conditions by registered trial count.

6 US clinical trials · 4 currently recruiting · #2,866 of 28,707 conditions by registered trial count

Tauopathies: 6 US clinical trials tracked, 4 recruiting.

Tauopathies is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is University of Pennsylvania, running 4 of these trials.

Enrollment posture brief

Registry condition tauopathies

OPEN 4 | RECR 67% | LATE 0 | EARLY 4 | RANK #2866 | SPON 4

Nearest open-share peer: Adenocarcinoma of Lung (67% recruiting · 6 trials)

Tauopathies (this)67%Acute Hypoxemic Respiratory 66.7%Abdominal Aortic Aneurysms50%Acupuncture50%Acute Lymphoblastic Leukemia50%
Open-enrollment share among volume-matched conditions near Tauopathies

Tauopathies lists 4 open slots (67% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Tauopathies on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Tauopathies is recruiting above its size-band peers.

    4 of 6 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Tauopathies research.

    University of Pennsylvania accounts for 4 of 6 trials (66.7%). 3 distinct sponsors appear on at least one study for this condition label.

  3. Most Tauopathies trials plan to enrol fewer than 100 people.

    Median target enrolment is 80 among the 6 trials that report a genuine target (sentinel values excluded). 6 of those (100%) plan for fewer than 100 participants.

  4. Tauopathies research is mostly interventional.

    6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 14

Phase Distribution

PhaseTrial count
Phase 1 4

Top Sponsors

Named interventions

Most-linked intervention names on Tauopathies records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Amyloid PET Diagnostic test
2 trials
Brain MRI Diagnostic test
2 trials
Neurological assessments Behavioral
2 trials
[18F]T807 ([18f]mni-777) Drug
1 trials
Harmony at HOME (H@H) Behavioral
1 trials
Neurologic exam Behavioral
1 trials
Brain MRI Scan Diagnostic test
1 trials
Neurological Assessments Behavioral
1 trials

US sites by state

Facility locations filed on Tauopathies trials. A trial with sites in several states counts in each.

Pennsylvania 4 trials
Connecticut 2 trials
Missouri 1 trials
Kentucky 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Tauopathies page

6 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Tauopathies condition card totals 6 registered trials; most-linked intervention Amyloid PET; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.